Literature DB >> 6596907

Synergy of imipenem or penicillin G and aminoglycosides against enterococci isolated from patients with infective endocarditis.

J A Indrelie, W R Wilson, J Y Matsumoto, J E Geraci, J A Washington.   

Abstract

We tested the synergistic activity of imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK 0787) (20 micrograms/ml) or penicillin (20 micrograms/ml) in combination with increasing concentrations of either streptomycin (5, 10, and 20 micrograms/ml) against 13 strains of streptomycin-susceptible enterococci or gentamicin (1, 3, and 5 micrograms/ml) against 13 strains of streptomycin-susceptible enterococci and 7 strains of streptomycin-resistant enterococci. At 24 h, penicillin together with each increment in streptomycin concentration resulted in a significant increase (P less than 0.001) in killing of streptomycin-susceptible enterococci compared with imipenem and the corresponding concentration of streptomycin. Similarly, at 24 h, the magnitude of killing of streptomycin-susceptible enterococci by a combination of penicillin plus each increment of gentamicin concentration was significantly greater (P less than 0.001) than that of the combination of imipenem and the corresponding concentration of gentamicin. Against streptomycin-resistant enterococci, penicillin together with each increment of gentamicin concentration killed significantly more enterococci (P less than 0.02) than did the combination of imipenem and the corresponding concentration of gentamicin. When combined with an aminoglycoside, the synergistic activity in vitro against enterococci of imipenem was significantly less than that of penicillin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6596907      PMCID: PMC180048          DOI: 10.1128/AAC.26.6.909

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; N Patel
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

2.  Synergism between N-formimidoyl thienamycin and gentamicin or tobramycin against enterococci.

Authors:  C Watanakunakorn; J C Tisone
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

3.  Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis.

Authors:  R C Moellering; O M Korzeniowski; M A Sande; C B Wennersten
Journal:  J Infect Dis       Date:  1979-08       Impact factor: 5.226

4.  Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.

Authors:  R Auckenthaler; W R Wilson; A J Wright; J A Washington; D T Durack; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

5.  Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside.

Authors:  G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

6.  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.

Authors:  W K Livingston; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

7.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

8.  N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.

Authors:  D Hanslo; A King; K Shannon; C Warren; I Phillips
Journal:  J Antimicrob Chemother       Date:  1981-06       Impact factor: 5.790

  8 in total
  4 in total

Review 1.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 2.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

3.  [Dosage of imipenem/cilastatin].

Authors:  P M Shah
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 4.  Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.

Authors:  Yuan Liu; Ziwen Tong; Jingru Shi; Ruichao Li; Mathew Upton; Zhiqiang Wang
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.